Opportunity Information: Apply for RFA DK 27 125
The National Institutes of Health (NIH) is offering a limited-competition Notice of Funding Opportunity (NOFO) titled "Limited Competition for the Continuation of the Caring for OutPatiEnts after Acute Kidney Injury (COPE-AKI) Clinical Centers (U01 Clinical Trial Required)" (Funding Opportunity Number: RFA DK 27 125). This opportunity uses a cooperative agreement mechanism (U01), meaning NIH will have substantial scientific and programmatic involvement in the work rather than serving only as a funder. The purpose is not to start a brand-new study, but to extend and complete an already ongoing NIH-supported clinical trial effort focused on outcomes and care strategies for people who survive serious acute kidney injury (AKI) after hospitalization.
The NOFO is designed to provide a 3-year extension of the existing COPE-AKI clinical trial consortium. The consortium structure includes three participating Clinical Centers (CCs) and one Scientific and Data Research Center (SDRC). The extension is intended to help the consortium fully reach its recruitment and enrollment goals, finish follow-up for enrolled participants, and ensure the infrastructure and staffing needed for high-quality data management, statistical analysis, and dissemination of results. In other words, the funding is meant to carry the current trial to completion and to support the final phases that often determine whether a clinical trial produces clear, actionable evidence.
A central rationale for this continuation is that there is currently no widely accepted standard of care for patients after they leave the hospital following AKI. Many patients, particularly those with more severe AKI (Stage 2 and Stage 3), face substantial risks after discharge, including recurrent kidney injury, progression to chronic kidney disease, cardiovascular complications, rehospitalization, and other downstream health problems. COPE-AKI is positioned to generate evidence that can directly inform better clinical management strategies for these survivors, with the longer-term goal of shaping or establishing a standard of care for post-hospital AKI follow-up and treatment.
This is a true limited competition: only the current awardees under the earlier COPE-AKI funding announcement (RFA-DK-20-011) are eligible to apply. Eligibility is restricted to the institutions that employ the Program Director/Principal Investigator of the original COPE-AKI participating Clinical Centers and the COPE-AKI Scientific Data Research Center. This restriction is meant to ensure continuity of operations, consistency of trial procedures, and preservation of the existing trial governance and infrastructure, which are critical when extending a complex multi-site clinical trial.
Foreign participation is explicitly restricted. Non-U.S. entities (foreign organizations) cannot apply, non-U.S. components of U.S. organizations are not eligible, and foreign components (as defined by the NIH Grants Policy Statement) are not allowed. The activity category is health, and the CFDA/Assistance Listing number associated with this opportunity is 93.847.
Applications submitted under this NOFO will go through NIH standard peer review, and only those judged meritorious will be considered for funding. The anticipated number of awards is three. The original application due date (closing date) listed for this opportunity is 2026-11-06, and the NOFO was created on 2026-08-31. The award ceiling is not specified in the provided source information, suggesting applicants will need to consult the full NOFO details (particularly budget guidance and any institute-specific limits) to understand allowable costs and expected award sizes.
Overall, the opportunity is best understood as a targeted, continuity-focused extension meant to bring COPE-AKI to full completion: finishing enrollment, completing participant follow-up, and supporting final analyses and publication/dissemination so that the study results can meaningfully influence clinical practice for survivors of moderate to severe AKI.Apply for RFA DK 27 125
- The National Institutes of Health in the health sector is offering a public funding opportunity titled "Limited Competition for the Continuation of the Caring for OutPatiEnts after Acute Kidney Injury (COPE-AKI) Clinical Centers (U01 Clinical Trial Required)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.847.
- This funding opportunity was created on 2026-08-31.
- Applicants must submit their applications by 2026-11-06. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- The number of recipients for this funding is limited to 3 candidate(s).
- Eligible applicants include: Others.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Frequently Asked Questions (FAQs)
What is the name of this NIH funding opportunity?
The Notice of Funding Opportunity (NOFO) is titled "Limited Competition for the Continuation of the Caring for OutPatiEnts after Acute Kidney Injury (COPE-AKI) Clinical Centers (U01 Clinical Trial Required)."
What is the funding opportunity number?
The funding opportunity number is RFA DK 27 125.
Which NIH funding mechanism is being used?
This opportunity uses a cooperative agreement mechanism (U01).
What does a U01 cooperative agreement mean for NIH involvement?
A U01 cooperative agreement indicates that NIH will have substantial scientific and programmatic involvement in the supported work, rather than acting only as the funding source.
What is the purpose of this NOFO?
The purpose is to extend and complete an already ongoing NIH-supported COPE-AKI clinical trial effort, not to launch a new study. The extension supports reaching recruitment and enrollment goals, completing participant follow-up, and carrying out final data-related and dissemination activities needed to bring the trial to completion.
How long is the extension period supported by this NOFO?
The NOFO is designed to provide a 3-year extension of the existing COPE-AKI clinical trial consortium.
Is this opportunity intended to start a brand-new clinical trial?
No. It is a continuation/extension opportunity intended to support completion of an existing COPE-AKI clinical trial consortium effort.
What are the main activities the continuation funding is meant to support?
Based on the provided description, the continuation funding is intended to support: (1) fully reaching recruitment and enrollment goals, (2) completing follow-up for enrolled participants, and (3) ensuring the staffing and infrastructure needed for high-quality data management, statistical analysis, and dissemination of results.
What is COPE-AKI focused on?
COPE-AKI focuses on outcomes and care strategies for people who survive serious acute kidney injury (AKI) after hospitalization, with an emphasis on generating evidence that can inform clinical management after hospital discharge.
Why is NIH extending this consortium instead of ending it on the original timeline?
The continuation is positioned as a way to ensure the consortium can fully meet recruitment/enrollment targets, complete follow-up, and finish the analyses and dissemination that determine whether a multi-site clinical trial produces clear, actionable evidence.
What clinical gap is this research trying to address?
A central rationale is that there is currently no widely accepted standard of care for patients after they leave the hospital following acute kidney injury (AKI). The trial is intended to generate evidence that could inform better post-hospital management strategies and potentially shape a standard of care for follow-up and treatment after AKI.
Which AKI patient population is highlighted as being at higher risk after discharge?
The description highlights that many patients, particularly those with more severe AKI (Stage 2 and Stage 3), face substantial risks after discharge.
What types of post-discharge risks are mentioned for AKI survivors?
The opportunity description cites risks such as recurrent kidney injury, progression to chronic kidney disease, cardiovascular complications, rehospitalization, and other downstream health problems.
How is the COPE-AKI consortium structured?
The consortium structure includes three participating Clinical Centers (CCs) and one Scientific and Data Research Center (SDRC).
How many awards does NIH anticipate making under this NOFO?
The anticipated number of awards is three.
Who is eligible to apply?
This is a limited competition. Only the current awardees under the earlier COPE-AKI funding announcement (RFA-DK-20-011) are eligible to apply. Eligibility is restricted to the institutions that employ the Program Director/Principal Investigator of the original COPE-AKI participating Clinical Centers and the COPE-AKI Scientific Data Research Center.
What prior funding announcement is referenced for eligibility?
The prior funding announcement referenced is RFA-DK-20-011.
Is this a true limited competition?
Yes. The description explicitly states it is a true limited competition with eligibility limited to current COPE-AKI awardees from the earlier announcement.
Are foreign organizations allowed to apply?
No. Foreign participation is explicitly restricted: non-U.S. entities (foreign organizations) cannot apply.
Are non-U.S. components of U.S. organizations eligible?
No. The description states that non-U.S. components of U.S. organizations are not eligible.
Are foreign components allowed under this NOFO?
No. Foreign components (as defined by the NIH Grants Policy Statement) are not allowed.
What is the activity category for this opportunity?
The activity category is health.
What is the CFDA/Assistance Listing number for this opportunity?
The CFDA/Assistance Listing number associated with this opportunity is 93.847.
Will applications be peer reviewed?
Yes. Applications will go through NIH standard peer review, and only those judged meritorious will be considered for funding.
What is the application due date listed in the provided information?
The original application due date (closing date) listed is 2026-11-06.
When was this NOFO created?
The NOFO was created on 2026-08-31.
Is the award ceiling (maximum award amount) specified in the provided information?
No. The award ceiling is not specified in the provided source information. Applicants would need to consult the full NOFO for budget guidance, allowable costs, and any institute-specific limits.
What is the overall goal of this continuation funding?
The overall goal is to bring the COPE-AKI clinical trial to full completion by finishing enrollment, completing participant follow-up, supporting final analyses, and publishing/disseminating results so the findings can meaningfully inform clinical practice for survivors of moderate to severe AKI.
Browse more opportunities from the same category: Health
Previous opportunity: U.S. Department of Justice FY26 Coordinated Tribal Assistance Solicitation Notice of Funding Opportunity
Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for RFA DK 27 125
Applicants also applied for:
Applicants who have applied for this opportunity (RFA DK 27 125) also looked into and applied for these:
| Funding Opportunity |
|---|
| Cooperative Centers for Experimental Hematology (CCEHs) (U54- Clinical Trial Not Allowed) Apply for RFA DK 27 127 Funding Number: RFA DK 27 127 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Infectious Diseases Clinical Trials Network (IDCTN) (UM1 Clinical Trial Required) Apply for RFA AI 27 002 Funding Number: RFA AI 27 002 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Limited Competition: Institutional Development Award (IDeA) for Clinical & Translational Research (CTR) (P30 - CT Optional) Apply for PAR 27 056 Funding Number: PAR 27 056 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Paul B. Beeson Emerging Leaders Career Development Award in Aging (K76 Clinical Trial Not Allowed) Apply for PAR 27 112 Funding Number: PAR 27 112 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Limited Competition: NIGMS Mature Synchrotron Resources (MSR) for Structural Biology (P30 - Clinical Trial Not Allowed) Apply for PAR 27 068 Funding Number: PAR 27 068 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Long-term health outcomes of people living with spina bifida Apply for CDC RFA DD 26 0222 Funding Number: CDC RFA DD 26 0222 Agency: Centers for Disease Control - NCBDDD Category: Health Funding Amount: $300,000 |
| Clinical Research Network on Antimicrobial Resistance (UM1 Clinical Trial Required) Apply for RFA AI 27 005 Funding Number: RFA AI 27 005 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Lasker Clinical Research Scholar's Program (Si2/R00 Clinical Trial Optional) Apply for PAR 27 076 Funding Number: PAR 27 076 Agency: National Institutes of Health Category: Health Funding Amount: $499,000 |
| Single Source for the Continuation of the Epidemiology of Diabetes Interventions and Complications (EDIC) Study Research Center (Collaborative U01 Clinical Trial Not Allowed) Apply for RFA DK 27 112 Funding Number: RFA DK 27 112 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Exploratory Clinical Neuroscience Research on Substance Use Disorders (R61/R33 Clinical Trial Optional) Apply for PAR 27 053 Funding Number: PAR 27 053 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Development of Candidate Medical Countermeasures (MCMs) and Technologies Against Radiological/Nuclear or Chemical Threats (U01 Clinical Trial Not Allowed) Apply for RFA AI 27 014 Funding Number: RFA AI 27 014 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Trauma Care Readiness and Coordination Cooperative Agreement Apply for EP U3R 26 002 Funding Number: EP U3R 26 002 Agency: Assistant Secretary for Preparedness and Response Category: Health Funding Amount: $500,000 |
| Improving the Capacity of Tribal Communities to Identify Emerging Drug Threats Apply for RD ET RDA 26 002 Funding Number: RD ET RDA 26 002 Agency: Office of National Drug Control Policy Category: Health Funding Amount: $300,000 |
| Cancer Prevention and Control Programs for State, Territorial, and Tribal Organizations Apply for CDC RFA DP 27 0023 Funding Number: CDC RFA DP 27 0023 Agency: Centers for Disease Control - NCCDPHP Category: Health Funding Amount: Case Dependent |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Inside Our Applicants Portal
Access Applicants Portal
- Grants Repository - Access current and historic funding opportunities with ease. Thousands of funding opportunities are published every week. We can help you sort through the database and find the eligible ones to apply for.
- Applicant Video Guides - The grant application process can be challenging to follow. We can help you with intuitive video guides to speed up the process and eliminate errors in submissions.
- Grant Proposal Wizard - We have developed a network of private funding organizations and investors across the United States. We can reach out and submit your proposal to these contacts to maximize your chances of getting the funding you need.
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Learn More
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "RFA DK 27 125", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.